Achim A. Jungbluth

Papers

Total Citations

H-Index

About

Achim A. Jungbluth is a distinguished pathologist and translational researcher whose work focuses on cancer immunology, diagnostic pathology, and the development of novel biomarkers. He is best known for his pioneering contributions to the characterization and clinical application of cancer-testis (CT) antigens, particularly the NY-ESO-1 antigen, which has become a cornerstone in cancer vaccine and immunotherapy research. His studies have advanced the understanding of antigen expression in various malignancies, including melanoma, lung, and ovarian cancers, and have facilitated the development of targeted immunotherapies. Jungbluth’s research also encompasses the validation of RNAscope® in situ hybridization for detecting TERT mRNA, a tool with significant diagnostic and prognostic utility in histopathology. With over 6,000 citations, his work has had a profound impact on both basic cancer biology and clinical practice. Notably, his 2022 paper on TERT mRNA expression exemplifies his ongoing commitment to bridging molecular diagnostics and patient care. Jungbluth’s career is marked by a dedication to translating laboratory discoveries into practical applications that improve cancer diagnosis and treatment.